Product image of Lamisil (Terbinafine) supplied by GNH India

Lamisil

Active Ingredient:
Terbinafine
Origin:
EU

Lamisil (Terbinafine)

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as an oral dosage form for oral use. It treats dermatophyte infections such as athlete’s foot, body ringworm, and fungal nail infections in adult patients and are commonly prescribed for superficial mycoses of the skin and nails.

GNH India supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is available for bulk distribution across Europe, Asia, Africa and the Americas.

Manufacturer / TM Owner

Novartis Farma - Produtos Farmacêuticos S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lamisil (terbinafine) is used to treat fungal infections affecting the skin, hair and nails.

  • Tinea pedis (athlete’s foot): eradicates the dermatophyte causing foot skin infection.
  • Tinea corporis (body ringworm): clears the fungal infection of the body skin.
  • Onychomycosis (fungal nail infection): promotes regrowth of healthy nail by eliminating the causative fungus.
  • Tinea cruris (jock itch): treats fungal infection of the groin area.
  • Tinea capitis (scalp ringworm): eliminates the fungus causing scalp infection.

How It Works

  • Terbinafine exerts its antifungal activity by selectively inhibiting the fungal enzyme squalene epoxidase. This blockade prevents conversion of squalene to lanosterol, leading to accumulation of toxic squalene and depletion of ergosterol, an essential component of fungal cell membranes. The resulting membrane destabilization halts fungal growth and leads to cell death, impairing replication of the organism.

Side Effects

Oral terbinafine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort or dyspepsia.
  • Headache: mild to moderate intensity.
  • Taste disturbance: altered taste perception or loss of taste.

Serious or Rare Side Effects

  • Hepatotoxicity: clinically significant liver injury or hepatitis.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Peripheral neuropathy: numbness, tingling or burning sensations in the limbs.

Precautions & Warnings

Before prescribing oral terbinafine, clinicians should consider several precautionary measures to ensure patient safety.

  • Liver function assessment: obtain baseline hepatic enzymes and monitor periodically.
  • Drug interactions review: evaluate concomitant medications that affect CYP2D6.
  • Pregnancy and lactation counseling: avoid use unless benefits outweigh potential risks.
  • Renal impairment adjustment: assess kidney function in patients with severe renal disease.
  • Age considerations: use caution in elderly patients due to increased risk of adverse effects.
  • Store at ambient temperature: keep below 25 °C in the original container, protect from moisture.

Avoid Interactions

Terbinafine can interact with other medicines, altering its concentration or the effect of co‑administered drugs.

Major Interactions (Avoid)

  • Itraconazole: combined use may increase risk of hepatotoxicity.
  • Cimetidine: may raise terbinafine plasma levels, enhancing toxicity.

Moderate Interactions (Monitor Closely)

  • CYP2D6 substrates (e.g., fluoxetine, paroxetine): terbinafine can inhibit metabolism, requiring dose adjustment.
  • Warfarin: may potentiate anticoagulant effect, monitor INR.
  • Antacids containing aluminum or magnesium: may reduce terbinafine absorption, separate dosing.

Frequently Asked Questions

Lamisil (terbinafine) is prescribed for dermatophyte infections such as athlete’s foot (tinea pedis), body ringworm (tinea corporis), groin itch (tinea cruris), scalp ringworm (tinea capitis), and fungal nail infections (onychomycosis). It targets the fungi that cause these superficial mycoses.

Terbinafine inhibits the fungal enzyme squalene epoxidase, blocking the conversion of squalene to ergosterol. This leads to toxic squalene buildup and loss of ergosterol, a key component of fungal cell membranes, causing membrane destabilisation and fungal cell death.

The prescribed dose of Lamisil is set by the treating physician based on the type and severity of the infection, patient weight, renal and hepatic function, and any relevant drug‑interaction considerations. No fixed regimen is provided here.

Safety data for terbinafine in pregnancy and lactation are limited. It is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss risks and alternatives with the patient.

To request Lamisil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals such as itraconazole or fluconazole, terbinafine has a different target (squalene epoxidase) and often achieves higher cure rates for dermatophyte infections, especially onychomycosis. However, drug‑interaction profiles and hepatic safety must be evaluated for each patient.

Lamisil should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lamisil is taken orally, usually with a full glass of water. It can be taken with or without food, but consistency with meals is recommended to maintain steady absorption. Patients should follow the prescriber’s instructions regarding timing and duration of therapy.

Serious adverse events include hepatotoxicity (liver injury or hepatitis), severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and peripheral neuropathy presenting as numbness or tingling. Any signs of these conditions require immediate medical attention.

Lamisil is contraindicated in patients with known hypersensitivity to terbinafine or any component of the formulation. Caution is advised for individuals with pre‑existing liver disease, severe renal impairment, or those taking medications that strongly interact with terbinafine metabolism.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Terbinafine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT